FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Analytical Food Laboratories CGMP Violations

FDA warns Grand Prairie, TX-based Analytical Food Laboratories about CGMP violations in its work as a drug contract testing laboratory.

Medical Devices

FDA Clears SimBioSys TumorSight Expanded Use

FDA clears a SimBioSys 510(k) for TumorSight Viz to expand its use by breast surgeons through artificial intelligence-based image processing.

latest-news-card-1
Biologics

Merus Zeno BLA Gets 3 Month Review Extension

FDA extends by three months its priority review of a Merus BLA for Zeno (zenocutuzumab) for treating patients with certain types of lung and pancreati...

latest-news-card-1

Support, Suggestions for FDA Rare Disease Hub

Four rare disease stakeholders say they support an FDA plan to create a Rare Disease Innovation Hub and suggest its initial priorities.

latest-news-card-1
Medical Devices

Lawyer Says Not Enough FDA Digital Health Standards

Attorney Bradley Thompson says he is surprised and disappointed that FDA is not approving enough new consensus standards to support digital health and...

latest-news-card-1
Human Drugs

Pilot Evaluating Quicker Reviews for Some Drugs

FDA announces a pilot program designed to expedite the review of new therapies addressing unmet medical needs.

latest-news-card-1
Biologics

Clinical Holds Lifted on 3 CARsgen Cell Products

FDA removes the clinical holds on three CARsgen Therapeutics clinical trials evaluating CT053, CT041, and CT071.

latest-news-card-1
Human Drugs

Phase 3 Study on Disc Medicines Bitopertin

FDA agrees on a Phase 3 study design for Disc Medicines bitopertin and its use in treating a rare sunlight sensitivity disorder.

latest-news-card-1
Human Drugs

Quanta Dialysis Home Dialysis Device Cleared

FDA clears a Quanta Dialysis Technologies 510(k) for the use of its Quanta Dialysis System in the home setting.

latest-news-card-1
Human Drugs

Mark Cubans Generic Operation Hit with 483

Mark Cubans Cost-Plus Manufacturing and Compounding facility in Dallas, TX, receives a Form FDA-483 based on findings from a recent inspection.